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Abstract
Erythrocytes and platelets are the major cellular components of blood. Several hereditary 
diseases affect the production/stability of red blood cells (RBCs) and platelets (Plts) result-
ing in anemia or bleeding, respectively. Patients with such disorders may require recurrent 
transfusions, which bear a risk to develop alloantibodies and ultimately may result in trans-
fusion product refractoriness. Cell culture models enable to unravel disease mechanisms, 
and to screen for alternative therapeutic products. Besides these applications, the ultimate 
goal is the large-scale production of blood effector cells for transfusion. Cultured RBCs that 
lack many of the common blood group antigens and Plts-lacking HLA expression would 
improve transfusion practice. Large numbers of RBCs and Plts can already be generated 
using hematopoietic stem cells derived from fetal liver, cord blood, peripheral blood, and 
bone marrow as starting material for cell culture. The recent advances to generate blood 
cells from induced pluripotent stem cells provide a donor-independent, immortal primary 
source for cell culture models. This enables us to study developmental switches during 
erythropoiesis/megakaryopoiesis and provides potential future therapeutic applications. 
In this review, we will discuss how erythropoiesis and megakaryopoiesis are mimicked in 
culture systems and how these models relate to the in vivo process.
Keywords: transfusion, cell culture model, GMP conditions, defined culture medium, 
cultured red blood cells, erythropoiesis, megakaryopoiesis, induced pluripotent stem 
cells, bioreactors, clinical trials
1. Introduction
Blood cells are by far the most abundant cells of which our body is comprised. Red blood cells 
(RBCs, or erythrocytes) and platelets (Plts, or thrombocytes) circulate in the vascular system, 
whereas the white blood cells that form our immune system locate both in the vascular system 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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and in the tissues. RBCs are best known for their function as oxygen transporters and for the 
clearance of CO
2
. Plts exert a crucial function in homeostasis upon vascular damage but they 
also function during angiogenesis, innate immunity, inflammation, wound healing, cancer, and 
hemostasis [1, 2]. This chapter focuses on erythropoiesis and megakaryopoiesis. RBCs in the 
periphery have an average life span of 120 days, constituting approximately 45% of the blood 
volume. To maintain the population of RBCs, humans generate daily ~2 × 1011 reticulocytes 
[3]. Plts are shed by megakaryocytes (MK) and live approximately 8–9 days in humans, which 
require a production of ~8.5 × 1010 Plts/day [4, 5]. The generation of RBCs and Plts occurs mainly 
in the bone marrow (BM) in adults, although the lung has also been found to host megakaryo-
cytic progenitors as well as Plts-shedding MKs [6]. A small population of hematopoietic stem 
cells (HSCs) ensures the life-long generation of blood cells, although the HSCs themselves divide 
rarely. Mostly, HSCs that divide give rise to one new HSC and a daughter cell that develops to 
an actively dividing multipotent progenitor (MPP) (Figure 1) [7]. These MPPs undergo specifica-
tion through reciprocal actions of transcription factors (TF) that enhance or repress expression 
of lineage-specific TFs and direct the cells to a lineage-specific gene expression program [7]. 
Erythropoiesis and megakaryopoiesis were long thought to arise from a common progenitor, the 
megakaryocytic-erythroid progenitor, but recent lineage tracing indicates that MKs can also dif-
ferentiate directly from HSCs [8–10]. Not only MPPs, also erythroid progenitors (erythroblasts: 
Figure 1. HSC commitment to the erythroid/megakaryocytic lineages with lineage-specific marker expression pattern.
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EBLs) and megakaryocytic progenitors (megakaryoblasts: MKBLs) have extensive potential to 
undergo cell divisions before they commit to the final differentiation program to generate RBCs/
MKs. The final differentiation stages of both lineages have unique features. Erythroid progeni-
tors undergo 3–4 additional cell divisions with a short G1 cell cycle phase and without regaining 
the cell volume (i.e., loss of cell size control) [11–13]. MKBLs, instead, undergo 4–5 cell division 
cycles without cytokinesis, which results in a single cell with 64–128 genome copies (N = 64–128) 
[14]. Erythropoiesis and megakaryopoiesis also show spatiotemporal regulation. All blood cell 
progenitors including erythroid progenitors and MKBLs propagate in close contact with stromal 
cells that produce membrane-bound factors such as stem cell factor (SCF). Upon terminal dif-
ferentiation, erythroid progenitors bind to central macrophages that express receptors such as 
CD163, VCAM1, ICAM4, and CD163 to associate with EBLs [15–19]. Each macrophage binds 
several progenitors that undergo synchronous differentiation, which ends with phagocytosis of 
the extruded erythroid nucleus by the macrophage and release of reticulocytes into the circula-
tion. The mature MKs have to interact with the endothelial cells of the vasculature and protrude 
proplatelets into the capillaries, where shear stress contributes to the shedding of Plts [20].
Whereas steady state erythropoiesis and megakaryopoiesis of adult mammals take place in 
the BM and lung (MK), distinct anatomic sites of hematopoiesis are employed during devel-
opment (Figure 2A). After gastrulation, in humans, mesodermal precursor cells arise in the 
primitive streak, migrate to the yolk sac, and develop into blood islands (hemangioblasts), 
which produce primitive RBCs, primitive MKs, and macrophages [21]. During this process, 
basic fibroblast growth factor (bFGF) influences the proliferation of the hemangioblast and 
thereby the production of hematopoietic cells [22]. bFGF is synergistic with vascular endothe-
lial growth factor (VEGF) signaling in this process [23]. The primitive RBCs express embryonic 
type of hemoglobins (Hbs), retain the size of the early EBLs, and lose their nucleus only after 
prolonged circulation. Their erythropoietin (EPO)-dependence is unclear at this early stage of 
development [24, 25]. The primitive MKs are thrombopoietin (TPO) independent, have low 
ploidy compared to adult MKs, and produce fewer Plts, but contrary to primitive erythroid 
cells, these cells migrate to the fetal liver, where their polyploidization is TPO dependent [26, 
27]. Erythroid-myeloid progenitors (EMPs) arise in the yolk sac from hemogenic endothelium 
(HE) through endothelial to hematopoietic transition (EHT) and give rise to the first intermedi-
ate definitive wave, producing RBCs with fetal type of Hbs, MKs, and other myeloid cells [21, 
28]. The EMPs migrate and colonize the developing fetal liver where they transiently produce 
definitive fetal RBCs and MKs. Permanent definitive hematopoiesis in the fetal liver depends 
on the “birth” of HSC in the aorta main arteries, and more specifically in the aorta-gonad-
mesonephros (AGM) region, where the first CD34+ HSC arises through EHT. These early HSCs 
are dependent on bone morphogenetic protein 4 (BMP4), VEGF, and bFGF secreted by “feeder 
cells,” which are located near the endothelial cells undergoing EHT, thereby promoting this 
transition [23, 29]. These HSCs home to the fetal liver to produce definitive fetal blood cells. 
From the fetal liver, the HSCs migrate to the final site of hematopoiesis; the BM, where they 
give rise to adult definitive blood cells. Perinatally, hematopoiesis also occurs in the spleen [30]. 
RBCs and Plts generated at distinct anatomic sites have distinct characteristics; for example, 
RBCs express different Hb molecules arising from different sites (Figure 2B). Hb consists of two 
α and two β subunits each bound to an iron-containing heme molecule. The α locus expresses ζ 
and α protein isoforms, the β locus expresses ε, γ (γ1 and 2), and β (β and δ) isoforms. Primitive 
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RBCs express Hbe consisting of ζ and ε isoforms (Portland 1: ζ
2
γ
2
; Portland 2: ζ
2
β
2
; Gower 1: ζ
2
ε
2
; 
Gower 2: α
2
ε
2
); fetal RBCs are characterized by HbF consisting of α and γ isoforms; adult RBCs 
express HbA consisting of α and β isoforms (HbA1) plus a small amount of HbA2 consisting of 
α and δ isoforms. Hbs can be used to distinguish RBCs originated from different developmental 
stages; however, in the megakaryocytic lineages, there is a lack of such markers.
Biochemical and molecular analysis of erythroid/megakaryocytic cells requires large cell num-
bers. The in vitro expansion and differentiation of erythroid and megakaryocytic progenitors 
from human fetal liver (HFL), cord blood (CB), BM, or peripheral blood enable the production 
of large cell numbers from distinct ontology and at defined stages of differentiation for basic 
research, drug testing, disease modeling, or translational purposes (Figure 3). Differentiation 
of pluripotent stem cell types such as embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) toward hematopoietic lineages allows to study early blood ontogeny, which 
is difficult to study in vivo as of ethical issues and availability of human material. The knowl-
edge gained by using the abovementioned culture systems is subsequently of great value to 
control the expansion and differentiation of erythroid/megakaryocytic cells from ESCs/iPSCs 
leading to donor-independent blood cell production (Figure 3).
Figure 2. Human erythropoiesis/megakaryopoiesis during development. (A) Schematic depiction of site-specific (yolk 
sac/fetal liver-AGM/bone marrow) blood production during ontogeny focusing on erythroid and megakaryocytic 
lineages. (B) Representative HPLC tracks, showing the Hb content of in vitro-cultured erythroid cells derived from 
primary sources originating from distinct anatomical sites. Fetal liver-erythroid cells express fetal Hbs (HbF). Cord blood 
is obtained at the time of birth when the fetal to adult Hb switch takes place, resulting a mix of HbF and HbA. PBMC/
MPB-derived erythroid cells produced by the bone marrow mainly express adult hemoglobins (HbA1, HbA2).
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The aim of this chapter is twofold. First, we provide background information of the basic pro-
cesses of erythropoiesis and megakaryopoiesis that underly the various cell culture models. 
Second, we provide details, interpret and compare results on current protocols to expand and 
differentiate erythroid and megakaryocytic progenitors.
2. Erythropoiesis/megakaryopoiesis
2.1. Growth factors and major regulators
2.1.1. Lineage- and stage-specific cytokines
Interleukins (ILs) activate cytokine receptors, which do not have enzymatic activity and recruit 
Janus Kinases (JAK1, JAK2, JAK3, TYK) to phosphorylate tyrosines in their intracellular tail 
Figure 3. Application of in vitro-derived blood products from different primary sources in basic research, drug discovery, 
and transfusion.
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that can subsequently recruit signaling molecules. Cytokine receptors are often expressed on a 
limited set of cell types/differentiation stages. IL-3 and IL-6 are cytokines that promote survival 
of hematopoietic stem/progenitor cells (HSPCs), but they do not act on EBL-specific stages. 
IL-9 synergizes with IL-3 to enhance both erythropoiesis and megakaryopoiesis [31, 32]. IL-1β 
is an inflammatory cytokine that signals via MyD88 to IRAK and NF-κB to inhibit cell growth, 
to induce expression of growth factors and the extracellular matrix, and to cause apoptosis in 
most tissues. In megakaryopoiesis, it enhances commitment and differentiation [33, 34].
Erythropoietin (EPO) is mainly produced by the kidney (80%) and partially in the liver (10–15%; 
30% upon stress erythropoiesis) [35, 36]. EPO binds and activates EPO receptor (EPOR) and 
functions as a survival factor during erythropoiesis [37, 38]. Deficiency of Epo and/or Epor 
causes embryonic lethality due to the failure of definitive fetal liver erythropoiesis leading 
to the lack of mature RBCs [24, 39–41]. Fetal livers of EPO-deficient embryos contain normal 
numbers of erythroid progenitors that can form colony-forming unit-erythroid (CFU-E) in vitro 
in the presence of exogenous Epo [39]. EPO shows cross-reactivity in human and mouse.
Thrombopoietin (TPO) is the ligand for the MPL receptor. MPL is well conserved between spe-
cies and TPO showing cross-reactivity between mouse and human. TPO has a direct effect on 
self-renewal and expansion of HSCs in the BM, but controls megakaryopoiesis as well [42]. 
MKs and Plts bind TPO and sequester it from the circulation. Upon activation, Plts release 
TPO into the plasma, thereby stimulating megakaryopoiesis. Thus, the number of Plts and 
their activation controls TPO levels [43]. TPO is mainly produced by hepatocytes in the human 
liver. TPO production is increased when hepatocytes bind damaged and aged desialylated 
Plts via the Ashwell-Morell receptor. In a JAK2/STAT3-dependent manner, this activates TPO 
transcription and thereby regulates Plt production, HSC renewal, and expansion [42, 44, 45].
2.1.2. Growth factor-binding tyrosine kinase receptors
The tyrosine kinase receptors directly cross-phosphorylate tyrosine residues in their own 
cytoplasmic tail, and they phosphorylate downstream effector molecules. They are more 
widely expressed compared to cytokine receptors.
Stem cell factor (SCF; first described as the Steel locus) signals via the mast/stem cell growth 
factor receptor KIT (CD117; White locus). SCF cooperates with other cytokines in order to 
maintain the viability of HSPCs, and their proliferation/differentiation ability [46–48]. SCF is 
produced by the stromal cells in the BM as a secreted soluble factor but also as a membrane-
bound factor. A specific mutation in SCF (Steel-Dickie) disrupting the membrane form of 
SCF leads to severe anemia, indicating that the membrane-bound form is crucial at least for 
erythropoiesis [49]. In addition, Kit-deficient mice (W/W) suffer from neonatal lethality due 
to severe anemia [50, 51]. Besides its function on HSPC, SCF is particularly important upon 
blood loss, to enhance proliferation and delay differentiation of the erythroid and megakaryo-
cytic progenitors [52–54]. In contrast to TPO and EPO, SCF is not interchangeably reactive 
between mouse and human—mouse SCF activating both, while human does not.
FLT-3-ligand (FL) binds to Fms-like tyrosine kinase 3 (FLT-3 (CD135)) as its receptor. FL is an 
important growth factor for CD34+ HSPC by controlling their proliferation. Underscoring its 
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function, activating mutations in the FLT-3 receptor are prominent in acute myeloid leukemia 
[55]. FL, however, has a limited role in terminal MKBL/EBL differentiation because FLT-3 is 
not expressed on committed cells.
Insulin (Ins) and Insulin-like growth factor-I (IGF-I) bind the Ins receptor (InsR) and IGF-I receptor 
(IGF1R). Both receptors are very well conserved between species to the extent that Ins even 
cross-reacts between mammals and birds. The homology between the receptors suggested that 
Ins may also act through the IGF1R, which is not true. IGF-I has a general cell survival function 
mediated by PI3K activation [56]. Human erythroid progenitors (pro-EBLs, early basophilic 
EBLs) express the IGF1R, and not the InsR, which changes during differentiation when the InsR 
becomes the prominent receptor [57]. InsR signaling is particularly important to control traf-
ficking of GLUT4 glucose transporters to the cell membrane [58]. Late EBLs and mature RBCs 
depend on glycolysis and EBLs express high levels of glucose transporters [59]. Upregulation 
of GLUT4, however, is also required for import of glutamine, required for nucleotide synthesis 
[60]. Because Ins and IGF-I act in physiological concentrations, their effect on in vitro cultures is 
not noticed in the presence of serum or plasma [61, 62].
2.1.3. Ligand-activated TFs
Steroid hormone receptors are the best known nuclear hormone receptors. In addition to these 
ligand-dependent TFs that bind DNA through a Zinc-finger domain, other ligand-activated 
TFs exist such as the aryl hydrocarbon receptor (AhR) that binds DNA through a helix-loop-
helix domain.
Glucocorticoids bind the glucocorticoid receptor (GR), a nuclear hormone receptor, which 
translocates to the nucleus upon association with its ligand, where it functions as a transcrip-
tional repressor and activator of gene expression. The GR homodimer binds to glucocorticoid 
response elements that consists of two inverted repeats. As a heterodimer with for instance 
STAT5, it only needs a “halfmer” GRE, i.e., a single repeat combined with the STAT5 binding 
site [63, 64]. The ligand of the GR is glucocorticoid (in vivo) produced by the adrenal gland. 
Several synthetic ligands have been designed to be used as immunosuppressive agents (e.g., 
dexamethasone—DEX). The GR exerts its immunosuppressive function at pharmaceutical 
levels of glucocorticoids, and as a monomer that binds and inhibits other TFs such as NF-κB or 
FOS/Jun dimers [65]. In contrast, stress erythropoiesis in vivo, and expansion of EBL cultures 
in vitro, is induced at physiological levels of glucocorticoids and depends on dimerization of 
the GR and on the ligand-dependent transcription activation domain [66, 67]. Polymorphisms 
of the GR may alter the expansion potential of EBLs [68].
3,5,3 -triiodothyronine (T3) binds the α and β thyroid hormone receptors (TRα, TRβ). T3 defi-
ciency is associated with anemia, although it is not clear whether this is caused by a direct 
effect on erythropoiesis [69, 70]. The effect of T3 appears to be highly species and develop-
mental stage specific. T3 has a potent differentiation promoting effect on avian erythropoiesis, 
but mouse EBLs are only sensitive to T3 during neonatal spleen erythropoiesis [71, 72]. In 
cultures of human erythroid cells, T3 enhances synchronous differentiation to enucleated 
reticulocytes [73].
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StemRegenin 1 (SR-1) binds and inhibits the AhR, which mediates toxicity of environmental 
pollutants, by binding to specific DNA enhancer sequences. This receptor can be activated 
by endogenous or exogenous ligands and contributes to several physiological processes, 
among which cell migration, apoptosis, and cell growth [74–77]. Importantly, AhR-deficient 
mice have increased numbers of BM HSCs [78]. The AhR functions in complex with the AhR 
Nuclear Translocator to induce differentiation by regulating genes directly such as c-MYC 
and C/EBP. During hematopoietic differentiation, its targets also include PU.1, β-CATENIN, 
CXCR4, and STAT5 [79]. Currently, the antagonist of AhR (SR-1) is used in clinical trials to 
expand CB-CD34+ cells prior to transplantation, thereby reducing the number of CB units 
needed per transplant from 5 to 1 [80]. Importantly, SR-1 also enhances in vitro proplatelet for-
mation [81]. To achieve proper Plts production, MKs have to produce an extensive membrane 
system; the demarcation membrane system. This requirs extensive lipid biosynthesis which 
can be inhibited by AhR [82]. Thus, blocking the inhibition of AhR with SR-1 may increase the 
proplatelet formation, through increasing the lipid membrane biosynthesis.
2.1.4. Erythroid-specific regulation
EPO is sufficient for steady-state erythropoiesis, when proliferative signals are mediated through 
the EPOR-associated RON receptor and EPO-induced differentiation is dependent on STAT5 
[83, 84]. Increased erythropoiesis during development and upon blood loss requires the coop-
erative action of the EPOR and KIT [85]. Activation of KIT prevents differentiation and propa-
gates the long-term proliferation of erythroid progenitors through inhibition of FOXO3a and 
activation of mRNA translation via the PI3K/mTOR pathway [86, 87]. Activation of the GR is 
required for stress erythropoiesis and to inhibit in vitro differentiation. Interestingly, gluco-
corticoids activate largely the same growth inhibitory genes in EBLs and in immune cells, but 
growth inhibition is counteracted by EPOR/KIT activation [88]. Even in the presence of serum, 
glucocorticoids promote selective proliferation of erythroid progenitors by both supporting 
erythroid proliferation and inhibiting proliferation of other myeloid and lymphoid cells [57].
Erythropoiesis is also regulated by the availability of iron, which is imported into the cell as 
holotransferrin via the transferrin receptor (TfR; CD71), and by selenium through selenopro-
teins [89, 90]. In vivo, erythropoiesis is dependent on the formation of erythropoietic islands 
that form around a central macrophage [91, 92]. Whereas CD169 macrophages are essential 
for erythropoiesis in vivo, high level of enucleation can be achieved in vitro in the absence of 
macrophages (van den Akker and von Lindern, manuscript in preparation) [93]. The com-
plete understanding of which macrophage signals control enucleation in vivo may further 
optimize the in vitro production of erythrocytes for transfusion purposes.
2.1.5. MK-specific regulation
TPO is the main regulator of megakaryopoiesis, and multiple other factors can work synergis-
tic with it. IL-6 can, in conjunction with TPO, increase hepatic TPO synthesis [94]. This effect is 
through the shared usage of gp130 and amplification of the same downstream JAK pathways 
[95]. The direct admission of IL-6, besides its effect on TPO, results in increased polyploidiza-
tion and subsequently leads to an enhanced Plts production in patients [96]. IL-11 is not con-
stitutively expressed but was shown to be induced in thrombocytopenia patients undergoing 
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BM transplantation. Exposure of IL-11 on HSPCs directly leads to an inhibition of NF-κB 
signaling, which suppresses miR-204-5p, that targets and represses the expression of TPO 
[97]. Because of this effect on TPO, it has a dual role in MK differentiation, first, in the expan-
sion of HSCs, second, in the terminal differentiation of MKs. In a similar way, IL-9 synergizes 
with IL-3 as well as with IL-4 and SCF to increase the yield of MKBL [33, 98]. Furthermore, 
the addition of IL-1β promotes selective megakaryocytic differentiation. IL-1β can increase the 
production of Plts by enhancing the effects of SDF1 and FGF4 that are produced by BM niche 
cells. IL-1α was shown to induce MK rupture and is considered as a stress megakaryopoiesis 
regulator [99].
Inhibition of AhR by SR-1 slows the differentiation program in HSCs, leading to increased 
expansion, and has a direct effect on MK differentiation, by slowing and/or conditioning cells 
to have a more synchronized maturation [74, 79, 81]. Through its effect on PU.1, it can influ-
ence RUNX1 which is one of the TF-regulating megakaryopoiesis. The introduction of SR-1 
into in vitro MK cultures results in increased cell size, higher polyploidization, and proplatelet 
production. In these cultures, a specific MK precursor population is identified that has an 
increased potential to produce proplatelets [81].
2.2. Cell culture models
2.2.1. Erythroid immortalized cell lines
2.2.1.1. Mouse cell lines
The most widely used immortalized mouse erythroid cell lines are MEL cells, which are EBLs 
transformed by Friend Leukemia virus. The viral gp55 protein activates the Epor to sustain 
cell growth, whereas integration of the virus upstream of PU.1 or Friend leukemia integration 
1 (Fli-1) induces constitutive high expression and inhibits differentiation. Leukemogenesis 
and the establishment of cell lines require additional inactivation of tumor suppressor pro-
tein p53 [100]. Under conditions that enable transient expansion of primary mouse cultures 
(serum-free medium supplemented with Epo, SCF, and glucocorticoids), lack of p53 is suf-
ficient to establish immortalized cell lines with full differentiation potential in the absence of 
SCF and glucocorticoids [13].
2.2.1.2. Human cell lines
Deletion of p53 is not sufficient in human to establish immortalized erythroid cell lines. 
However, expression of the human papilloma virus E6/E7 proteins in EBLs differentiated 
from iPSC gave rise to the HiDEP cell line [101]. The E6/E7 proteins inactivate both p53 and 
retinoblastoma tumor suppressor proteins [102]. They are expressed from a doxycycline (dox)-
inducible vector allowing for unlimited growth in the presence of EPO, SCF, and dox, and 
differentiation in the presence of EPO but without dox and SCF. Lack of p53 does not affect 
differentiation, but retinoblastoma is required for terminal erythroid differentiation [103–105]. 
Dox-inducible expression was also used to establish immortalized erythroid cells lines from 
CB (HUDEP) and from adult EBLs cultured from CD34+ HSPC (BEL-A) [106, 107]. The HiDEP, 
HUDEP, and BEL-A express embryonic, fetal, and adult Hbs, respectively [101, 107].
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2.2.2. MK-cell lines
Multiple cell lines have been generated to study megakaryopoiesis with among them; 
MEG-01 (suspension cells) and DAMI (adherent/suspension cells) both megakaryoblastic 
leukemia cell lines [108, 109]. These cell lines are mostly positive for MK-specific markers 
(see in Section 2.3.3) but are not a homogenous population. Although they proliferate in a 
MKBL-like state with some spontaneous differentiation and limited terminal differentiation, 
they can be induced to differentiate by the addition of phorbol myristate acetate. Under 
these conditions, the cells can become polyploid, increase their expression of MK-associated 
proteins, like von Willebrand factor, and are able to produce proplatelets although with low 
efficiency. Mechanistic insights were uncovered with these lines; for example, the forma-
tion of long, beaded cytoplasmic extensions of MKs that yield platelets upon shear stress. 
This process was also observed in normal healthy MKs in vivo, showing the usefulness of 
this artificial system to study fundamental processes [110]. Despite the usefulness of these 
lines, their genetic background (patients with genetic abnormalities) can influence mega-
karyopoiesis, resulting in incomplete differentiation and potential abnormalities that could 
possibly be linked to their immortalization process. As such, they are suboptimal models to 
study megakaryopoiesis and specifically MK polyploidization, synthesis of granules, and 
proplatelet formation.
2.3. Primary cell culture
2.3.1. Cell source and media
RBCs and MKs can be cultured for research and clinical applications from multiple primary 
tissue sources including HFL, CB, BM, mobilized peripheral blood (MPB), and peripheral 
blood mononuclear cells (PBMC). HFL is obtained from abortions on medical indication. 
HFL-derived erythroid cells express HbF and can be expanded to large numbers and dif-
ferentiated to hemoglobinized enucleated RBCs. For MK culture, this source is less ideal, 
mainly because of the harshness of the isolation method. Ethical concerns rule out HFL as a 
general source for transfusion, but with proper consent allows research into fetal hematopoi-
esis development. A widely available and ethically accepted source is CB which is commonly 
used for production of both erythroid cells and MKs. CB is obtained at birth when Hb-switch 
occurs from HbF to HbA1 (γ to β switch) and both Hb types are expressed in CB-derived 
cultures. The presence of HSPCs with a fetal hematopoietic program in CB has notable effects 
in the MK cultures. MKBL expansion is high; MK polyploidization and proplatelet formation 
are decreased compared to cultures of adult cells. As adult hematopoietic source, either BM 
or PBMC can be applied. BM is a limited source that can be more difficult to obtain, but does 
yield large quantities of HSPCs that can differentiate to erythroid and MK lineages. HSPCs 
can also be isolated from PBMCs, which is less invasive therefore a less limited source. This 
makes PBMC an ideal source to scale-up RBC production. The HSPC percentage in PBMC 
is significantly lower compared to BM, which can be enhanced by leukophoresis and by 
mobilizing BM HSPCs using G-CSF (10 μg/kg) alone or in combination with CXCR4/CXCL12 
inhibition [19, 111]. G-CSF alone leads to 5–30% mobilization [15]. HSPC mobilization is 
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caused by the downregulation of adhesion and chemokine processes and by the loss of BM 
macrophages [15, 112–115]. The mobilization can cause side effects for the donor, including 
headaches, fatigue, vomiting, muscle pain, bone pain, thrombocytopenia, citrate toxicity, etc., 
in which females experience the most adverse events [116]. These MPBs are ideal for RBC/Plt 
production because of their HSPC richness.
The MKs can be cultured in Cellgro (Corning), and both cell types can be cultured in StemSpan 
(Stem Cell Technologies) or other Iscove’s modified Dulbecco’s medium (IMDM)-based media. 
We generated a completely defined GMP-grade medium called Cell-Quin (Migliaccio et al. with 
minor modifications) that is highly efficient in expanding and differentiating EBLs/RBCs and 
MKs/Plts, with the ability to culture other hematopoietic progenitors and blood cell types [117].
2.3.2. Erythroid-specific culture system
Several parameters characterize the differentiation stage of erythroid cells. Expansion of EBL 
cultures is only possible when they maintain cell size control during their cell cycle, which 
is achieved by the cooperative action of SCF and glucocorticoids [12, 13, 118]. Terminal dif-
ferentiation in the presence of EPO involves 3–4 cell divisions during which cells’ surface 
marker expression changes and gets smaller due to loss of cell size control until cell cycle 
arrest and extrusion of their nuclei, concurrently, accumulating Hb [119]. Thus, surface 
marker expression pattern, cell size and morphology (enucleation), Hb content, and cumula-
tive cell numbers are a measure of differentiation (Figure 4A–C). Morphological features of 
the cells (nuclei-cytoplasm ratio, hemoglobinization, nuclei condensation, and polarization) 
are commonly assessed by cytospins coupled with Giemsa/benzidine stainings (Figure 4A). 
The purity of the erythroid population and its distribution over different maturation stages 
can be assessed by monitoring the progression of various cell surface markers. Commonly 
used markers are CD36, CD71 (transferrin receptor), CD117, and the erythroid-specific mark-
ers band 3 (SLC4A1) and CD235 (glycophorin A). The generally accepted dynamics of these 
markers during erythroid differentiation: pro-EBLs (immature EBL stage) are characterized 
by CD34−/CD36+/CD117+/CD71high/CD235low/−, while during expansion phase, EBLs gain 
CD235 expression and become CD117+/CD71+/CD235+. In terminal differentiation phase, EBLs 
remain positive for CD235 and lose their expression of CD117 followed by the gradual loss of 
CD71, which is associated with reticulocyte formation [120].
The first human erythroid culture systems utilized the knowledge obtained from genetics, 
e.g., discoveries in the field of cytokines, growth factors, and their receptors. In these first 
protocols, HSPCs were expanded in the presence of IL-3, SCF plus or minus IL-6. It is fol-
lowed by a step in which the resulting erythroid progenitors were further expanded and 
differentiated in the presence of EPO [121]. This protocol was modified, using low EPO con-
centrations in step 1 (0.5 U/ml) and high concentrations (>3 U/ml) in step 2 [122]. Others 
used high concentrations of EPO throughout step 1 and step 2 [123, 124]. These two-step 
protocols are based on the original protocol of Fibach and coworkers who employ IMDM 
supplemented with serum or plasma [121]. Serum and plasma contain factors that support 
erythropoiesis in these cultures. The major factor in the serum is transforming growth factor 
β (TGFβ), which is a potent differentiation factor for erythropoiesis [57, 125]. These cultures 
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show a high degree of spontaneous differentiation, which is often used to study expansion 
and differentiation of EBLs carrying a genetic defect. The quality differences between serum 
batches and the use of different cytokines make these culture protocols difficult to compare. 
Two major changes increase the yield of these erythroid cultures and enable synchronous 
differentiation. First, glucocorticoids cooperate with SCF to retain pro-EBLs and early baso-
philic EBLs in their undifferentiated state [57, 126]. Second, serum-free medium avoids the 
differentiation promoting effect of TGFβ. However, the available serum-free media are sub-
optimal and require complementation with lipids [73]. Even better expansion is achieved with 
a serum-free medium optimized for expansion of EBLs [117]. The differentiation arrest in 
the presence of glucocorticoids and the absence of serum enables the expansion of a homo-
geneous early EBLs culture that can undergo up to 20 cell divisions to achieve a million-fold 
Figure 4. Characteristics of erythroid and megakaryocytic cultures. (A) Erythroid-specific morphology by cytospin 
with Giemsa/benzidine staining. Left: pro-EBL, right reticulocytes. (B) Erythroid expansion growth curve from PBMCs 
(n = 4). (C) Flow cytometry of terminal erythroid differentiation, DNA staining by DRAQ5 resulting in three distinct 
populations: DRAQ5+ big cells: nucleated EBLs (red); DRAQ5+ small cells: nuclei (blue); DRAQ5− cells: enucleated 
reticulocytes (purple). (D) MK-specific morphology by cytospin with MGG-staining. Left: MKBL; right: polyploid MK 
(arrows). (E) Proplatelet-forming MK (arrows (beads on a string)).
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expansion [73, 119]. Using Cell-Quin, we can obtain 2 × 1010 EBLs within 16 days, starting from 
5 × 107 PBMCs (Figure 4B). Expansion of EBLs in the presence of serum and in the absence of 
glucocorticoids irrevocably results in differentiation and transfer of the cells to differentiation 
conditions. Of note, addition of glucocorticoid agonists in a serum-based culture will still 
induce spontaneous differentiation due to the presence of TGFβ [57]. At any moment during 
expansion phase, cells can be transferred to differentiation conditions in which the medium 
is supplemented with EPO, Ins, and low level of plasma/serum [119, 120]. Although expan-
sion of EBL cultures is achieved in serum-free medium, terminal differentiation to enucleated 
cells requires at least 2% serum or plasma [119, 120]. Using Cell-Quin medium, we currently 
obtain >90% enucleation, a deformability that corresponds to values between freshly isolated 
reticulocytes and erythrocytes, and normal oxygen association and dissociation values (van 
den Akker and von Lindern, manuscript in preparation). We use DRAQ5 staining coupled 
with flow cytometry analyses to quantify reticulocyte/nuclei/nucleated cell ratio (Figure 4C). 
Flexibility is measured on a ARCA, and oxygen binding by the Hemox analyzer [127, 128].
2.3.3. MK-specific culture system
Commitment of MKBL and differentiation of MKs can be monitored by the expression of cell 
surface markers and by the morphological features of the cells (Figure 4D and E). MKBLs are 
characterized by CD34+/CD41a+ expression and blast-like morphology. In terminal differen-
tiation, MKs gradually lose their expression of CD34+, leading to a subdivision of stages: early 
MKs are CD34+/CD41a+/CD42+ and late MKs are CD34−/CD41a+/CD42+.
To obtain large numbers of MKBLs, SCF/FL and TPO are used during the first 4–7 days of 
cultures started from CD34+-HSPCs. TPO without SCF and FL allows terminal differentia-
tion to proplatelet-forming cells. To increase the expansion potential, IL-3 can be included 
only in the initial phase as its prolonged exposure directs the HSPC toward the monocyte/
granulocyte lineage. With the addition of IL-6, the MK specification and TPO signaling can be 
enhanced. With the addition of either IL-1β, IL-9, or IL-11 during the first phase of CD34+ dif-
ferentiation, MK commitment is enhanced instead of progenitor proliferation. It is important 
to determine the main goal of an experiment before starting the culture: does the experiment 
require large numbers of MKBLs, or should MK enrichment be maximal, because a good 
expansion of MKBL tends to compromise terminal differentiation and vice versa (Hansen and 
van den Akker, unpublished results). Factors such as IL-1β and IL-9 increase polyploidiza-
tion, formation of proplatelets, and Plts shedding. There is some concern about using IL-1β, 
because of its proinflammatory nature. Particularly, as it is closely related to IL-1α, and the 
increased Plt shedding may cause rupture of MKs [33, 99]. To introduce proplatelet forma-
tion, IL-6 can be used in high concentrations (>100 ng/ml), by itself or in combination with 
TPO. SR-1 influences megakaryopoiesis on an early and late stage of the culture, as described 
above, having a positive effect on the expansion of HSC and terminal differentiation of MK 
[80, 81]. During the terminal stages of MK cultures (during proplatelet formation), it becomes 
increasingly essential to prevent the activation of the MKs and produced proplatelets. The 
addition of heparin prevents the coagulation of plasma added to the media but cells are 
still able to clump together, thereby having a negative impact on the differentiation and 
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Figure 5. Erythroid/MK differentiation of iPSC according to Hansen et al. showing the different phases of differentiation, 
with their corresponding growth factor combination and morphological changes [136].
proplatelet production. To prevent activation, signaling via the GPIIb/IIIa (ITGA2B) receptor 
can be blocked with tirofiban hydrochloride monohydrate. Whereas an MK sheds thousands 
of Plts in vivo, shedding large amounts in vitro from a single MK has not yet been achieved. 
In vivo of this process requires that proplatelets extrude between the endothelial cells of the 
blood vessel wall into the capillaries. This increases level of SP1 among others, combined with 
shear stress of the blood flow is required for the Plts to be released. To mimic this in vitro, 
several specialized bioreactors are being tested (see Section 2.5).
2.4. Erythropoiesis/megakaryopoiesis from iPSC
Pluripotent stem cells offer a novel approach for developmental studies, drug screening/
discovery, disease modeling, and regenerative medicine. ESCs originate from the inner cell 
mass of a blastocyst stage embryo, while iPSCs are somatic cells that are reprogrammed 
back to this embryonic stage [129–132]. Hematopoietic differentiation of ESC/iPSC cells 
follows the various stages of blood development from early embryonic stages (Figure 2A). 
This offers a valuable tool to study early human hematopoiesis which is difficult because of 
ethical issues and tissue availability. Besides, differentiation of iPSCs opens opportunities for 
large-scale manufacture of blood products with the expectancy of clinical application [133]. 
Several groups showed the potential of ESCs in blood cell production, the source which 
was later replaced by iPSCs with similar outcome including our group (Figure 5) [134–140]. 
The published protocols generally include four culture phases: (1) mesoderm induction, 
(2) hematopoietic/erythroid/megakaryocytic commitment, (3) expansion of the specific cell 
pool, and (4) terminal maturation. The hematopoietic differentiation phases in vitro are 
directed by stepwise addition of cytokines. This is commonly achieved by BMP4, bFGF, and 
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VEGF that drive the cells toward mesoderm, followed by the addition of IL-3, IL-6, SCF, and 
TPO stimulating hematopoietic specification. Lineage-committed progenitors can be further 
differentiated toward mature cell types, which is achieved by the combination of medium, 
growth factors, and hormones. Although most of the differentiation protocols are following 
the abovementioned scheme, including the listed growth factors, there are multiple technical 
variations during iPSCs differentiation toward hematopoietic lineages. Two main technical 
details underlie the major differences in the applied protocols: (i) the induction of differen-
tiation as a 2D monolayer versus 3D embryoid body formation and (ii) the use of coculture 
with feeder versus feeder-free systems [141–144]. The choice of the differentiation system 
depends on the application need. 3D systems more closely resemble the in vivo process in 
comparison to 2D systems, offering a tool to study embryogenesis [141, 144–147]. 2D sys-
tems, however, are relatively simple, more reproducible, and therefore suitable to scale up 
production, enabling clinical application [77, 148–150]. The choice of feeder-based or feeder-
free differentiation similar to 2D/3D systems also depends on the purpose of the specific 
research question. Feeder-based coculture systems more resemble the niche, including sec-
retome and cell-cell contact; however, for future clinical application, feeder-free systems are 
imperative [142, 143, 151, 152]. Protocols can also differ in timing, in the applied media and 
cytokine cocktails used, which makes comparisons between research groups and methods 
difficult. Stemline II (SIGMA) is a widely applied base medium during the first and, in some 
cases, the second phase in feeder-free settings [138, 149, 153]. From the second/third phase 
onward, the same basic medium are applied that are generally used for other definitive blood 
cell types such as IMDM with serum/holotransferrin/lipid/Ins supplementation or StemSpan 
(Stem Cell Technologies) [137, 138, 150, 153]. From the second-step onward, we apply Cell-
Quin which in comparison to StemSpan was more efficient in their iPSC-erythroid expansion 
potential (Figure 6A). Some methods still include BMP4, VEGF, and bFGF (or either of them) 
at this second stage, typically in embryoid body-based system because the 3D structures are 
less homogenous. Therefore, the transition between phases is not entirely uniform and clear 
[140, 149, 154, 155]. The few feeder-free 2D systems that have been published mostly do not 
rely on these three additional factors during commitment phase [148, 149]. FL is also used in 
erythroid/MK commitment cytokine mixes to improve progenitor expansion [140, 154]. MK 
commitment/expansion is always based on TPO with or without the addition of multiple 
other cytokines (e.g., IL-1β, IL-9, IL-11) [99, 136, 156–158].
As pointed out before, early erythropoiesis/megakaryopoiesis (yolk sac) in humans is not 
well studied, resulting in a lack of knowledge on the regulatory program at these develop-
mental stages. Therefore, the generally applied cytokines might not ideally mimick the in vivo 
situation or the iPSC-driven hematopoietic program. This could underlie inefficient iPSC to 
RBC/MK differentiation. For example, EPO is applied in all systems to induce erythropoiesis; 
however, the role of EPO during primitive wave is not entirely clear. Disruption of EPO and/
or EPOR causes embryonic lethality in mice due to the failure of the definitive fetal liver 
erythropoiesis with reduced primitive erythropoiesis, suggesting that EPO and EPOR are 
already functional in early yolk sac [24, 25, 39–41]. However, others showed that additional 
EPO did not affect heme synthesis in early mouse embryos [159]. Furthermore, Malik et al. 
found that EPOR-null embryos have normal number of primitive, early stage progenitors but 
subsequently develop anemia with loss of primitive EBL [24]. In line with these findings, the 
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same group concluded that EPO signaling is not critical for the survival of human primitive 
erythroid progenitors, but have a less understood role to promote proliferation and matura-
tion of these cells. Since the role of EPO is controversial in yolk sac erythropoiesis, we tested 
whether iPSC-erythroid commitment is EPO-dependent. We have tested the requirement 
of the two most important growth factors for definitive erythropoiesis in various combina-
tions; EPO and SCF (Control), without EPO (-EPO), without SCF (-SCF), and without both 
cytokine (-EPO and -SCF) [136]. Without EPO, we noticed lower harvest rate/colony number 
and the loss of CD71/CD235 population. The erythroid commitment was not affected by the 
deprivation of SCF; however, the addition of SCF together with EPO resulted in a more pure 
CD71/CD235 population (Figure 6B). These data suggest that EPO is required to allow early 
erythroid commitment while the role of SCF is not entirely clear.
Introduction of erythroid/MK-specific TFs into iPSC-derived hematopoietic cells, often named 
“forward reprogramming”, is being pursued as an approach to improve differentiation out-
come. HOXA9, ERG, RORA, SOX4, and MYB have been introduced into human pluripotent 
stem cells. Engraftment into NSG mice resulted in erythroid cells, which were more skewed 
to definitive erythropoiesis (lack of embryonic Hbs, mainly HbF and some HbA, some enucle-
ation) compared to TF-free counterparts [160, 161]. These results suggest the possibility of 
Figure 6. Optimization of iPSC-erythroid differentiation cultures. (A) iPSC-derived erythroid cells arose (D12+0) and 
expanded in Cell-Quin or StemSpan media. (B) Representative FACS-plots of iPSC-derived erythroid cell (D12 harvest), 
with or without EPO and SCF from day 6 onward.
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more mature erythroid cell production from iPSCs if certain TFs are included; however, the 
in vitro feasibility is not provided presently. To direct the cells more lineage-specific, other 
lineage instructive TFs may be used. GATA1, FLI-1, and TAL1 (MK-specific TFs) can be over-
expressed to direct iPSC to MKs, thereby achieving ~100% MK yield within 15 days [158]. 
Besides this set of genes, there are other combinations that are used to achieve a similar aim 
[156, 162].
The technical differences between published differentiation methods are leading to slight 
discrepancies in marker expression pattern, purity, yield, and stage of development. 
However, currently all published methods are limited by technical pitfalls, including the 
production of developmentally immature (nonadult) cell types which may be the cause of 
low yield and difficulty to terminally differentiate toward functional end stage blood cell 
types (e.g., low enucleation potential of iPSC-erythroid cells and low efficiency of iPSC-Plt 
formation).
2.4.1. Marker expression pattern of differentiating iPSC cells
The purity of the iPSC-derived erythroid population, and its distribution over different matu-
ration stages can be assessed by the erythroid-specific markers used for definitive erythroid 
culture systems (Section 2.3.2); however, their progression differs in some aspects. Based on 
our differentiation scheme (Figure 5), we recognize three maturation stages: (i) an early ery-
throid population (harvest at day 10–14) is CD71high/CD235high/CD36med/high, which is not yet 
hemoglobinized and displays big nuclei [136]. Furthermore, the cells are negative for CD18 
(myeloid lineage marker) confirming specification toward the erythroid lineage; (ii) a 100% 
pure erythroid population (day 7–9 expansion) is CD71/CD235/CD36med with some spontane-
ous differentiation, which is recognized by hemoglobinization and condensation of the nuclei; 
(iii) a mature erythroid population (D7-14 terminal differentiation) gives rise to CD235high/
CD71high/med/CD36low cells. However, there is a slight CD71 decrease associated with reticulocyte 
formation, and iPSC-derived erythroid cells do not become CD71 negative. Morphologically, 
these cells were somewhat different from their definitive counterparts. Despite hemoglobiniza-
tion, nuclear condensation, and polarization, we do not observe a decrease of cytoplasm size 
and the enucleation potential is poor. Technical variations in the published methods (timing, 
added growth factors) cause notable differences in the erythroid marker expression pattern; 
therefore, it is hard to compare and/or draw general conclusions. The emergence of CD71+/
CD235+ population is generally reported with purity discrepancies. For example, Yang et al. 
[163] reported 80% CD71/CD235 purity (with CD34+/CD43+ preselection and OP9 coculture), 
Salvagiotto et al. [148] by a feeder-free monolayer system reached 40% pure population, while 
Kobari et al. [135] with EB-based induction reached 98–99% comparable to our findings. The 
pattern of CD36 expression is not entirely clear. Mao et al., for example, used a four-step dif-
ferentiation scheme, including an AGM coculture induction step, and defined the following 
gene expression profile: early definitive EBLs derived from CD235+/CD34low/CD36−, and they 
develop to CD235+/CD34−/CD36−, CD235+/CD34−/CD36−/low, CD235+/CD34−/CD36− cells in 
sequence [164]. Others including us found high CD36 expression during the early erythroid 
stage [136].
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The kinetics during differentiation/maturation of MK from iPSC follow the same steps as from 
definitive CD34+ cells, namely MKBL (CD34+/CD41a+), early MK (CD34+/CD41a+/CD42+), and 
late MK (CD34−/CD41a+/CD42+). The MKs can undergo some polyploidization albeit not in 
similar level as in vivo or primary CD34+ cultures. MKs derived from mouse iPSC can form 
proplatelets but also in low numbers [157, 165–168]. These Plts can be activated and contribute 
to clot formation and wound healing when transfused to injured mice, showing that iPSC 
megakaryopoiesis, although still inefficient, leads to functional Plts. The MK-specific cell sur-
face markers can be also used for iPSC-MKs with the exception of CD41a. This marker is 
also an early endothelial/hematopoietic marker. Therefore, it is essential to always use it in a 
combination, for example, with CD42 to confirm the specific MK commitment. Despite this, 
most groups report MK percentage only based on CD41a expression (~30–80% MK induction) 
[136, 150, 168]. With our method, we are able to achieve an average purity of 78% (CD41a) that 
can be easily used in scaleup production [136].
2.4.2. Developmental stage of iPSC-derived erythroid/MK cells
Human ESC/iPSC-derived erythropoiesis/megakaryopoiesis, with the current knowledge, do 
not reach the adult definitive stage, but give rise to a mixture of primitive and definitive fetal/
adult cells. Very little is known about human erythropoiesis/megakaryopoiesis in the early 
stages, between days 17 and 23 of embryogenesis (yolk-sac, AGM region) due to the fact that 
abortions are primarily performed at later fetal stages and in addition have serious ethical con-
cerns. Hbs are commonly used to distinguish between developmental waves; however, HbF 
expressing RBCs both arises from yolk sac and later from fetal liver, and momentarily, there is 
a lack of markers, which can clearly distinguish these two waves (Figure 2A and B). The iPSC-
derived erythroid cells predominantly express HbF, in addition to embryonic types of Hb. 
We and others also showed the presence of a small portion of adult Hb [135, 136, 153–155]. 
From the embryonic type of globins, both the presence of Gower 1 and Gower 2 Hb has been 
reported, but the ratio greatly differs between methods [135]. The presence of Gower 2 Hb 
indicates that the cells are capable of the first globin switch (ζ to α) to provide more mature 
primitive-state RBCs. Interestingly, the presence of adult types of Hb also differs between 
protocols as some group were able to show HbA1 or the presence of β chain, whereas others, 
including us, observed mainly HbA2 [135, 155]. It is unknown whether primitive erythro-
poiesis in vivo goes through a stage that corresponds to iPSC-derived erythroid cells (Hbemid, 
HbFhigh, HbAlow/−) or whether globin synthesis is impaired in these cells. The globins, however, 
may not be the most accurate markers to define the waves. Altogether, these findings make 
it difficult to define the state of iPSC-RBCs with respect to their developmental stage. From a 
technical point of view, these cells are able to produce definitive RBCs; therefore, they poten-
tially can give rise to the required therapeutic product. Better understanding of the underlying 
regulatory mechanisms such as the site where erythropoiesis/megakaryopoiesis takes place, 
and Hb switches during development might pave the way for the necessary improvement of 
the current methods.
Unlike in the erythroid lineages where the expression of stage-specific Hbs can be used to 
determine the ontogeny phase, this type of readout is not available in the MK lineage. There 
are, however, intrinsic differences between megakaryocytic cells derived at different sites 
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during ontogeny. For instance, polyploidy is a measure of ontogeny in vivo as yolk sack 
MK exhibits low ploidy (4–8N), whereas adult MK reach >64N [14, 169, 170]. Besides the 
lower polyploidization, the number of Plts that are produced follows the same trend from 
a low number per MK in embryonic/fetal tissues too high numbers of in adult MK, linking 
polyploidization and MK size to Plts production [170]. However, ploidy levels and Plt pro-
duction in vitro are generally lower compared to their in vivo counterparts; therefore, it is not 
a good marker to access iPSC-MK development stages. The current best approach would be 
to use data from erythroid cultures and their ontogeny stage/wave and extrapolated this to 
the MK development because of their close relationship. However, investigation of purified 
megakaryocytic cultures of defined ontogeny stages through, e.g., RNAseq or mass spec-
trometry could yield specific makers.
2.4.3. Expansion potential/yield of iPSC-erythroid/MK cells
The final yield of our method is relatively high; however, the comparison with other methods 
is difficult due to technical discrepancies. There are different ways to calculate the final yield, 
which also depends on the iPSC maintenance system (single cell vs. clumps) and on the induc-
tion system (2D or 3D), resulting various ways to report the final yield. Single cell-seeded iPSC 
cultures can be normalized both to the initial number of seeded cells or to colony number. 
Furthermore, the comparison of absolute cell number produced (harvested) between 2D and 
3D systems is not entirely realistic because of the different nature of the two cultures. We use 
single cell-seeding, which allows to calculate the yield/iPSC and yield/colony number to rep-
resent differentiation efficiency. In our hands, one iPSC colony can give rise on average 5.6 × 
106 erythroid cells after 9 days of expansion. While a single iPSC gives rise to ~8 × 103 erythroid 
cells (harvest) and subsequent 9 days expansion results in ~2 × 105 erythroid cells/iPSC on 
average [136]. The expansion potential (from harvest day) compared to definitive cell types 
remains relatively low, in line with other methods irrespective of culture condition (Figure 4B). 
The terminal maturation of iPSC-erythroid cells toward enucleating reticulocytes is inefficient 
with the existing methods and is currently one of the major hurdles to overcome. In our hands, 
matured iPSC-erythroid cultures had 30–40% enucleation rate based on their nuclei count; 
however, the resulting reticulocytes appeared to be instable. Altogether, iPSC-derived ery-
throid cells are able to expand but for limited time and length, with suboptimal enucleation 
capacity. Probably, this is also coming from the fact that iPSC-derived erythroid cells, based on 
their globin expression, do not entirely correspond to a fetal/adult definitive wave.
MK yield from iPSCs is higher than CD34+ differentiation (6.9 × 103 cells/iPSC). Unlike the 
erythroid system in which differentiation can be inhibited for several days by the addition of 
glucocorticoid analogues, the megakaryocytic system currently lacks such a specific expan-
sion advantage. As a result, iPSC-MK yield and purity is currently low compared to the 
iPSC-erythroid yield. Even though the yield of MK is low, a small number of MK still could 
produce significantly large amount of Plts. The in vivo production of 2000–8000 Plts/MK is 
not achieved by far (1–50 Plts/MK in static condition) [4, 5, 81, 168]. Initiatives to increase this 
yield are needed but will require increasing our knowledge on the later stages of proplatelet 
formation, which is a current hurdle to overcome in culture conditions and further discussed 
in the next paragraph devoted to bioreactors (Section 2.5).
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2.5. Bioreactors
The production of cultured red blood cells for transfusion purposes has been the holy grail 
for transfusion medicine. However, a main challenge is the well-described limitation in cell 
density during the expansion phase [171]. A single transfusion unit contains 2 × 1012 RBCs. 
Conventional cultivation systems using dishes or flasks can reach up to 10 × 106 cells/mL, 
meaning that more than 1000 L of culture would be required for the manufacture of a single 
transfusion unit [172]. Handling of such large volumes is impractical if static culture condi-
tions are maintained. Thus, multiple bioreactor designs have been proposed to improve the 
volumetric productivity of the process (produced cells/volume of medium). A static culturing 
system mimicking BM tissue has been proposed, in which cells are grown in a porous scaffold 
and nutrients are continuously fed through hollow fibers, while used media containing waste 
from metabolism are removed [173]. This system allows to have continuous replenishment of 
spent components in the media, while it is possible to re-use some of the most expensive com-
ponents such as growth factors and transferrin. Also, it separates cells from large shear stress 
sources. Although an optimal design of this system could lead to the production of transfu-
sion units at competitive costs compared to the price of rare blood units, it would require 
significant improvements in transfer of nutrients and matured RBCs between the scaffold and 
the inflow/outflow streams [174]. Mass transfer limitations in diffusion-governed systems can 
be tackled with agitation. It is relevant to note that conflicting reports have been made on the 
effect of shear due to agitation in in vitro erythropoiesis [172, 175]. Nevertheless, important 
advances have been made toward culture of EBLs in stirred reactors. Enucleated RBCs were 
produced in microbioreactors (<20 mL) in which the effect of shear stress on expansion and 
enucleation of EBLs was evaluated. Gas sparging caused cell death, whereas stirring enhanced 
enucleation [172]. Expansion can also be performed in shake flasks (40 mL) and stirred tank 
bioreactors of larger volumes (500 mL) with similar growth kinetics [176]. Hybrid systems 
combining mechanical agitation and growth of cells in porous materials have also been pro-
posed. This type of systems could improve mass transfer while protecting cells from shear, 
but harvesting of mature cells from these carriers is still a challenge that must be addressed.
The high sensitivity of MK to shear stress renders culturing and flow cytometry assays chal-
lenging. However, it can also be exploited to generate in vitro Plts. Multiple techniques can be 
used to induce the culturing and shedding of Plts like pipetting or the use of flow chambers 
[157, 165–168]. These approaches mimic more the in vivo situation of Plts formation where 
they are shed in the vasculature, in contrast to static cultures. Plt shedding can be induced 
by repetitive pipetting of the cultured cells with a hand pipette (p1000) [81]. There is a risk 
that too much pressure is enforced on the cells, causing them to lyse instead of shed. A more 
sophisticated method of in vitro Plts production is the use of flow chambers, which come in 
different versions [167, 177]. The most basic one has a linear flow with a surface that is coated 
to which MKs can attach [165, 167]. These versions were further developed to chambers that 
include small gaps where MKs are trapped and can extend their cytoplasmic extensions 
through the gap where they start forming Plts [165, 177]. Another flow chamber setup is the 
use of pillars in the chamber instead of gaps where the MKs can attach. Coating with a various 
matrices like fibronectin, von Willebrand factor, or TPO can enhance the efficiency of the Plts 
generation. In addition, the flow rates that are produced in these chambers can be regulated. 
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The produced Plts in these systems can be harvested and used for functional test. The afore-
mentioned approaches can also be combined in a way that the culturing and differentiation 
of iPSC toward MK is performed on coated beads in a stirred spinner flask bioreactor, where 
subsequently also the Plt production is induced and enhanced, although with a relatively low 
Plt yield (1 Plt/MK) [168]. Recently, Ito et al. showed that in the vasculature, MKs are not only 
exposed to shear stress but also to turbulence during Plt sheading, where the process was 
implemented in their bioreactor [178]. By using their iPSC lines with inducible c-MYC-BMI-1 
and BCL-XL expression, they were able to produce a thrombocyte transfusion unit in an 8 L 
system. This approach proves the possibility of large-scale Plt production but still with a dis-
crepancy between in vitro (80–100 Plts) and in vivo (2000–8000 Plts) Plt production capacity.
2.6. Clinical trial
The ability to produce large numbers of enucleated, hemoglobinized RBCs opens the perspec-
tive of producing cultured red blood cells (cRBC) for transfusion purposes. The feasibility to 
do so has been demonstrated by the team of Luc Douay who cultured 1 mL of packed cRBC 
from CD34+ HSCs and transfused it to a healthy volunteer, with a cRBCs half-life of 26 days 
after injection [133, 179]. Donor-derived RBC transfusion is a cornerstone of modern medicine 
in the treatment of trauma, chronic anemia, and in surgery. The existence of 30 blood group 
systems, such as the ABO and Rhesus system, generates at least 300 distinct blood group 
antigens [180]. Recurrent transfusions carry an inherent risk on alloimmunization to non-
identical blood group antigens, which complicate further transfusions. Besides, this cellular 
therapy is dependent on donor availability with a potential risk of blood-borne diseases. In 
vitro derivation of cRBCs allows their thorough characterization, therefore providing access to 
better matched product. Improved cell culture protocols may eventually enable us to generate 
cRBCs for transfusion purposes from iPSCs that were selected and/or modified to lack most 
blood group antigens with the advance of donor-independency offered by iPSCs source.
In a recent publication, Ito et al. [178] were able to generate Plts in transfusion quantities, 
where the functionality of these Plts was shown in in vivo mouse experiments. This work gives 
a feasible prospect of clinical trials, which still requires the system to be converted to GMP 
grade [178].
Our culture protocol from human PBMC to RBC
• day 0 expansion: purify PBMCs by Ficoll and seed in StemSpan or Cell-Quin supplemented 
with 1 ng/ml human IL-3, 2 U/ml EPO, 10 ng/ml hSCF, 10−6 M DEX at 10 × 106 cells/ml, 37°C, 
and 5% CO
2
.
• Optional: to remove remaining RBCs after Ficoll purification, the use of RBC lysis buffer 
is suggested.
• day 2 and 4: replace half of the medium; add all factors to the medium except for IL-3.
• day 5: EBLs appear as large (nongranulated) blasts.
• Optional: to remove remaining lymphocytes, purify the culture by density centrifuga-
tion on a 1.075 g/ml Percoll gradient.
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• day 6–20: put the cells daily or every second day to 0.5–0.7 × 106/ml medium supplemented 
with EPO, SCF, and DEX (concentration is same as day 0).
• day 0 terminal differentiation: wash the cells twice with PBS and re-seed in medium sup-
plemented with 10 U/ml EPO, 1 mg/ml holotransferrin, 2–5% plasma, 5 U/ml heparin at 2 
× 106/ml.
• day 9–14: let the cells differentiate with half media change every 2–3 days.
Our culture protocol from CD34+ to MK
• day 0: collect CD34+ cells by MACS isolation from CB, BM, PBMC, or MPB and seed in 
Cellgro or Cell-Quin with 100 ng/ml FL, 50 ng/ml hSCF, 50 ng/ml TPO, 20 ng/ml IL-6 at 1 × 
106 cells/ml, 37°C, and 5% CO
2
.
• Re-seed cells when concentration exceeds 2.5 × 106 cells/ml, otherwise keep cells as 
undisturbed as possible at stable CO
2
 levels.
• day 4: cells start to commit to the MK lineage (~10–20%), cells are collected and spun down 
at 200 g to start terminal differentiation.
• day 0 terminal differentiation: re-seed cells in media (Cellgro or Cell-Quin) supplemented 
with: 50 ng/ml TPO and 10 ng/ml IL-1β at 0.5 × 106 cells/ml.
• During terminal differentiation, the addition of tirofiban hydrochloride monohydrate 
and heparin is recommended.
• Pipetting should be kept to minimal.
• 1 μM of SR-1 can be used to increase polyploidization and Plt production.
• day 11: cells will be committed to the MK lineage (80–100%) and consist of MKBLs and 
early MKs.
• Cell collection from these days onward should be performed using 2 mL or larger pipettes 
and avoid the usage of hand pipettes to circumvent cell lysis and shear stress [157, 166].
• Centrifugation steps are on 150 g, low ramp, and brake.
• Flow cytometry techniques on unfixed MKs at this stage will induce granule release and 
proplatelet formation.
• day 12–16: MK cells will mature to late MKs and start producing proplatelets.
• Centrifugation steps are 100 g, low ramp, and brake.
• CB starts proplatelet production earlier than adult sources.
• Proplatelets can be harvested using Plts isolation protocols.
• Proplatelets are easily activated, treat them as regular Plts.
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3. Conclusions
As described in this chapter, there are multiple protocols to culture RBCs and MKs from a 
variety of hematopoietic tissues. Depending on the goal (fundamental research, drug screen-
ing, or clinical applications), one should consider beforehand which source can be used. For 
clinical applications, the use of a fully defined unlimited source would be preferred. For this, 
iPSC (generated with nonintegrating method) hold great potential but differentiation toward 
RBCs and Plts has to be improved.
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